Text Size

The Serum Tissue Factor Level in Lung Cancer Patients as a Prognostic Factor

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2005 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00257179
First received: November 21, 2005
Last updated: March 13, 2006
Last verified: June 2005
History of Changes
  Purpose

This study uses serum tissue factor and tissue factor inhibitor and factor VII to monitor the pre-coagulation status in lung cancer patients and to correlate the pre-coagulation status with clinical staging and prognosis.


Condition
Lung Cancer

Study Type: Observational
Study Design: Allocation: Random Sample
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 200
Study Start Date: June 2005
Detailed Description:

The staging of lung cancer was according to tumor size, involvement of lymph node and metastatic status. But there is a different prognosis in cancer patients of the same stage. The coagulation status of cancer patients was considered as an important possible prognostic factor. So in this study, we want to evaluate patients' coagulation status and find the relation of coagulation status and cancer status.

We thus propose a prospective study using coagulation factors in order to search for the relationship between cancer stage and pre-coagulation status in Taiwanese lung cancer patients. We will also evaluate the potential use of tissue factor as a prognosis predictor in lung cancer patients.

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with newly-diagnosed lung cancer
  • Serum from cancer-free healthy volunteers

Exclusion Criteria:

  • Chronic renal failure or end-stage renal disease [ESRD] (creatinine [Cr] > 2 )
  • Hyperlipidemia on statin therapy
  • Acute myocardial infarction
  • Tapal or Plavix use
  • Active thromboembolic event
  • Severe liver disease (> child B)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00257179

Contacts
Contact: Chong-Jen Yu, M.D., Ph.D. 886-2-2356-2905 jeffery@ha.mc.ntuh.edu.tw

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Chong-Jen Yu, M.D., Ph.D.     886-2-2356-2905        
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Chong-Jen Yu, M.D., Ph.D. National Taiwan University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00257179     History of Changes
Other Study ID Numbers: 9461700609
Study First Received: November 21, 2005
Last Updated: March 13, 2006
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
Tissue factor
Lung cancer
Tissue factor protein inhibitor
Factor VII
Factor X

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
 Thromboplastin
Hemostatics
Coagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 16, 2013